Marshall Wace, LLP Calliditas Therapeutics Ab Transaction History

Marshall Wace, LLP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$12.85 - $20.36 $358,643 - $568,247	-27,910 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$15.14 - $25.55 $798,831 - $1.35 Million	-52,763 Reduced 65.4%	27,910 $518,000
Q4 2021 Feb 14, 2022	BUY	$15.04 - $26.32 $1.21 Million - $2.12 Million	80,673 New	80,673 $2 Million
Q2 2021 Aug 13, 2021	SELL	$26.02 - $31.17 $205,219 - $245,837	-7,887 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$27.01 - $32.92 $213,027 - $259,640	7,887 New	7,887 $218,000

20.3K

Ticker CALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,624,800
Market Cap $1.06B
Description
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment ...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.